CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 1, 2008--POZEN Inc.
(NASDAQ: POZN) announced today that John R. Plachetka Pharm.D., the
company's chairman, president and chief executive officer, will
present at Baird's 2008 Growth Stock Conference on Tuesday, May 13,
2008 at 10:40 a.m. (CT) at the Four Seasons Hotel in Chicago.
POZEN is a pharmaceutical company committed to developing
therapeutic advancements for diseases with unmet medical needs where
it can improve efficacy, safety, and/or patient convenience. POZEN's
efforts are focused primarily on the development of pharmaceutical
products for the treatment of acute and chronic pain and other
pain-related conditions. POZEN has development and commercialization
alliances with GlaxoSmithKline for Treximet(TM), which was recently
approved by the United States Food and Drug Administration for the
acute treatment of migraine attacks in adults, and with AstraZeneca
for proprietary fixed dose combinations of naproxen with the proton
pump inhibitor esomeprazole magnesium in a single tablet for
conditions such as osteoarthritis and rheumatoid arthritis in patients
who are at risk for developing NSAID-associated gastric ulcers. The
company's common stock is traded on The Nasdaq Stock Market under the
symbol "POZN". For detailed company information, including copies of
this and other press releases, see POZEN's website: www.pozen.com.
CONTACT: POZEN, Inc.
Chief Financial Officer
Director, Investor Relations
SOURCE: POZEN, Inc.